Valneva: The Lancet publishes article on VLA200
(CercleFinance.com) - Vaccine company Valneva today announced that the medical journal Lancet Infectious Diseases has published an article providing a detailed analysis of the clinical data from the pivotal Phase 3 trial for VLA2001, its inactivated whole-virus vaccine against Covid-19.
According to the paper, VLA2001 demonstrated higher levels of neutralising antibodies than the comparator vaccine, as well as a broad T-cell response against S-, M-, and N-proteins, and a significantly better safety profile.
Valneva published positive initial Phase 3 results for VLA2001 in October 2021. The company also published safety and immunogenicity data from the Phase 1/2 trial in the Journal of Infection in June.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
According to the paper, VLA2001 demonstrated higher levels of neutralising antibodies than the comparator vaccine, as well as a broad T-cell response against S-, M-, and N-proteins, and a significantly better safety profile.
Valneva published positive initial Phase 3 results for VLA2001 in October 2021. The company also published safety and immunogenicity data from the Phase 1/2 trial in the Journal of Infection in June.
Copyright (c) 2022 CercleFinance.com. All rights reserved.